semaglutide hockley More than half of all US adults are eligible for therapy Semaglutide - Effective Medical Weight

cardiovascular disease

Snapshot of the 2026 Speaker Faculty Top Takeaways: Unlocked the next generation of GLP-1 combinations and gained competitive intelligence on multi-agonist and combination therapies designed to enhance efficacy, minimize muscle loss, and improve body composition for superior patient outcomes Discovered high-value indication expansion and explored the next frontier of GLP-1 development beyond obesity through exclusive data on clinical programs targeting liver, renal and cardiometabolic disorders alongside neurological diseases and womens health conditions Mastered alternative delivery and patient adherence through dedicated sessions focused on overcoming the challenges of administration through oral programs and less frequent dosing strategies for long-term patient success Benchmarked against industry titans and innovators and heard directly from the companies leading the pipeline, including experts from Eli Lilly , Constructive Bio and Regeneron

Missing injections or stopping treatment because of side effects may interrupt progress and contribute to disappointing results

GLP-1 medications help bridge this gap, making it easier to achieve weight loss goals and lower the metabolic set point

Early studies have demonstrated a significant reduction in body weight, waist circumference, and blood glucose in adults with HO [66]

Retatrutide and NHS Access in the UK Retatrutide is not currently available on the NHS because it has not yet received regulatory approval in the UK